Hydroxychloroquine Chemoprophylaxis for COVID-19 Infection in High-risk Healthcare Workers.
Status:
Not yet recruiting
Trial end date:
2020-10-15
Target enrollment:
Participant gender:
Summary
Healthcare personnel are at an increased risk of exposure to SARS-CoV-2 infection while
handling such patients. Currently, there is no treatment available for SARS-CoV-2 and
stringent preventive measures are advised to avoid or minimize risk of exposure to healthcare
workers. There are in vitro studies available which show inhibition of corona virus by
hydroxychloroquine, a widely-used agent against malaria and certain autoimmune conditions and
of low-cost and limited toxicity. However, evidence regarding its effects in patients is
limited. We plan to conduct a randomized controlled trial to evaluate the safety and
potential prophylactic efficacy of hydroxychloroquine in preventing secondary SARS-CoV-2
infection among healthcare workers at high-risk of exposure while managing such patients.